WATER SOLUBLE POLYMER MICROSPHERES AS VACCINE VEHICLES

大多数病毒疫苗建立了一种系统保护状态 通过注射活的减毒或灭活的病毒制剂进行免疫。 可注射疫苗的使用降低了许多病毒的发病率 疾病。然而，它们的使用与一些不受欢迎的事情有关 副作用。减毒活病毒疫苗可能会导致系统性 并发症；灭活疫苗可能具有局部反应性，甚至 引起过敏状态。 使用可注射疫苗的另一种选择是粘膜 注射非复制性抗原。该病毒的一个主要焦点 研究所是对运输工具的研究。微胶囊化 是这项努力的核心技术。 SBIR第一阶段的工作目标是开发微球配置疫苗 以WE为基料的水溶性聚磷腈。这个目标将是 通过优化微球的大小和组成以及 确定给药剂量和粘膜途径，以最大化 单项抗体反应的速度、幅度和持续时间 抗原剂量。抗体应答在免疫球蛋白上的分布 Ig G亚类和细胞免疫的同工型 回应将会被确定。最后，防腐剂的保护效果 聚合物微球免疫方案将在动物模型中 已评估。

The majority of viral vaccines establish a state of systemic protective immunity by injection of live attenuated or inactivated virus preparations. The use of injectable vaccines has reduced the incidence of many viral diseases. Nevertheless, their usage is associated with some undesirable side effects. Live attenuated virus vaccines can cause systemic complications; inactivated vaccines can have local reactogenicity and even induce an allergic state. An alternative to the use of injectable vaccines is the mucosal administration of non-replicating antigens. A major focus of the Virus Research Institute is the study of delivery vehicles. Microencapsulation is the core technology in this endeavor. The SBIR Phase I work goal is to develop microsphere configured vaccine vehicles based on the we water soluble polyphosphazenes. This goal will be accomplished by optimizing size and composition of microspheres and determining the dose and mucosal route of administration that maximize the rapidity, amplitude and duration of the antibody response to a single antigen dose. The distribution of the antibody response over the Ig isotypes, as well as over the IgG subclasses and the cellular immune response will be determined. Finally, the protective efficacy of the polymer microsphere immunization regimen in an animal model will be evaluated.